@article{TCR10013,
author = {Elizabeth Dudnik and Nir Peled},
title = {Intracranial activity of crizotinib: something to rely on?},
journal = {Translational Cancer Research},
volume = {5},
number = {Suppl 4},
year = {2016},
keywords = {},
abstract = {Central nervous system (CNS) metastases remain a significant problem in the management of patients with ALK-rearranged non-small cell lung cancer (NSCLC). The frequency of CNS involvement in ALK-positive tumors is extremely high; it approaches 25% in treatment naïve patients (1) and rises to 50% in patients treated with crizotinib (2,3). Crizotinib was previously reported to have only minor intracranial activity (4), with poor CNS penetration suggested as the underlying mechanism (5).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/10013}
}